Related Experiment Video
Updated: Jan 14, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
The bleeding costs of intensive vs. less intensive antithrombotic strategies: a meta-regression analysis
Sten E Deurvorst1, Esther M E El-Hage2, Nienke van Wingerden3
1Department of Internal Medicine, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Insights
Intensifying antithrombotic therapy for atherosclerotic cardiovascular disease (ASCVD) reduces events but increases bleeding risk. Current regimens show no increased intracranial bleeding, but fatal hemorrhage remains a risk.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Evidence Synthesis
Background:
- Antithrombotic therapy is crucial for secondary prevention of atherosclerotic cardiovascular disease (ASCVD).
- The balance between antithrombotic efficacy and bleeding risk is not well understood.
- Comparative evaluation of antithrombotic regimens is challenging due to unclear risk-benefit correlations.
Purpose of the Study:
- To establish a benchmark for evaluating the trade-off between ASCVD prevention and bleeding risk.
- To systematically analyze existing trial data on antithrombotic therapy in ASCVD.
- To compare the efficacy and bleeding risks of different antithrombotic strategies.
Main Methods:
- Meta-regression analysis of 50 studies including 357,711 patients with ASCVD.
- Extracted data on major adverse cardiovascular events (MACE) reduction and bleeding events.
- Weighted generalized additive regression was used for data analysis.
Main Results:
- ASCVD event reduction correlated with increased intracranial hemorrhage risk.
- Reduction in acute coronary syndrome (ACS) and stroke associated with increased fatal hemorrhage risk.
- Excluding non-routine regimens attenuated intracranial hemorrhage risk, but fatal hemorrhage risk persisted.
Conclusions:
- Current antithrombotic regimens for ASCVD show no increased intracranial bleeding risk with intensified treatment.
- Fatal hemorrhage is an unavoidable consequence of intensified antithrombotic treatment for ASCVD, though absolute risks are low.
Aims:
Antithrombotic therapy is a cornerstone of secondary prevention of atherosclerotic cardiovascular disease (ASCVD). The main drawback of antithrombotic therapy is the associated bleeding risk. The correlation between the magnitude of antithrombotic efficacy and the severity of bleeding risk remains unclear, rendering the comparative evaluation of antithrombotic regimens based on their therapeutic advantages and risks challenging. This study aims to establish a benchmark for evaluating the trade-off between ASCVD prevention and bleeding risk through a systematic analysis of extant trial data.
Methods And Results:
Meta-regression analysis. We searched PubMed and Embase and extracted trials comparing antithrombotic treatments in patients with established ASCVD. We extracted data on major adverse cardiovascular events (MACE) reduction and bleeding events. A weighted generalized additive regression was used for data analysis. Our analysis included 50 studies, comprising a total of 357 711 patients with coronary artery disease (63%), cerebrovascular events (28%), and peripheral arterial disease (15%). Overall, ASCVD event reduction by intensification of antithrombotic therapy correlates with an increased risk of intracranial haemorrhage. Also, the reduction in the composite of acute coronary syndrome and stroke is associated with an increased risk of fatal haemorrhage. When regimens not routinely used in current practice are excluded, the increased risk of intracranial haemorrhage with intensified antithrombotic treatment is attenuated to non-significant, but ASCVD event reduction still correlates with an increased risk in fatal haemorrhage. The analyses and figures we present can serve as a benchmark to compare results of future trials on antithrombotic regimens for ASCVD to other (contemporary) regimens.
Conclusion:
With currently used antithrombotic regimens, ASCVD event reduction by more intensive treatment no longer increases risk of intracranial bleeding. Fatal haemorrhage remains a seemingly inevitable cost of ASCVD reduction by antithrombotic treatment intensification, albeit at low absolute risks.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management